WO2013163134A3 - Biomolecular events in cancer revealed by attractor metagenes - Google Patents

Biomolecular events in cancer revealed by attractor metagenes Download PDF

Info

Publication number
WO2013163134A3
WO2013163134A3 PCT/US2013/037720 US2013037720W WO2013163134A3 WO 2013163134 A3 WO2013163134 A3 WO 2013163134A3 US 2013037720 W US2013037720 W US 2013037720W WO 2013163134 A3 WO2013163134 A3 WO 2013163134A3
Authority
WO
WIPO (PCT)
Prior art keywords
attractor
metagenes
cancer revealed
biomolecular events
biomolecular
Prior art date
Application number
PCT/US2013/037720
Other languages
French (fr)
Other versions
WO2013163134A2 (en
Inventor
Dimitris Anastassiou
Wei Yi CHENG
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2013163134A2 publication Critical patent/WO2013163134A2/en
Publication of WO2013163134A3 publication Critical patent/WO2013163134A3/en
Priority to US14/519,795 priority Critical patent/US20150105272A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to compositions and methods for the independent and unconstrained identification of attractor metagenes as surrogates of pure biomolecular events as well as the use of such attractor metagenes in performing medical diagnosis, prognosis, and developing appropriate therapeutic regimes. The present invention is directed to compositions and methods for identifying an attractor from a data set.
PCT/US2013/037720 2012-04-23 2013-04-23 Biomolecular events in cancer revealed by attractor metagenes WO2013163134A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/519,795 US20150105272A1 (en) 2012-04-23 2014-10-21 Biomolecular events in cancer revealed by attractor metagenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637187P 2012-04-23 2012-04-23
US61/637,187 2012-04-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/519,795 Continuation US20150105272A1 (en) 2012-04-23 2014-10-21 Biomolecular events in cancer revealed by attractor metagenes

Publications (2)

Publication Number Publication Date
WO2013163134A2 WO2013163134A2 (en) 2013-10-31
WO2013163134A3 true WO2013163134A3 (en) 2014-01-16

Family

ID=49484017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/037720 WO2013163134A2 (en) 2012-04-23 2013-04-23 Biomolecular events in cancer revealed by attractor metagenes

Country Status (1)

Country Link
WO (1) WO2013163134A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016011612A (en) * 2014-03-11 2016-12-12 The Council Of The Queensland Inst Of Medical Res Determining cancer agressiveness, prognosis and responsiveness to treatment.
US10394898B1 (en) 2014-09-15 2019-08-27 The Mathworks, Inc. Methods and systems for analyzing discrete-valued datasets
CN109913420A (en) * 2019-03-07 2019-06-21 北京师范大学 Application of the CDC20 co-expression gene network as Treatment for Glioma target spot
CN113488123B (en) * 2021-04-21 2023-07-18 广州医科大学附属第一医院 Method for establishing diagnosis time-effect-based COVID-19 triage system, system and triage method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110265197A1 (en) * 2008-07-16 2011-10-27 Dana-Farber Cancer Institute, Inc. Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
WO2012047899A2 (en) * 2010-10-04 2012-04-12 The Johns Hopkins University Novel dna hypermethylation diagnostic biomarkers for colorectal cancer
WO2012056047A1 (en) * 2010-10-29 2012-05-03 Vib Vzw Metagene expression signature for prognosis of breast cancer patients
WO2013009705A2 (en) * 2011-07-09 2013-01-17 The Trustees Of Columbia University In The City Of New York Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110265197A1 (en) * 2008-07-16 2011-10-27 Dana-Farber Cancer Institute, Inc. Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
WO2012047899A2 (en) * 2010-10-04 2012-04-12 The Johns Hopkins University Novel dna hypermethylation diagnostic biomarkers for colorectal cancer
WO2012056047A1 (en) * 2010-10-29 2012-05-03 Vib Vzw Metagene expression signature for prognosis of breast cancer patients
WO2013009705A2 (en) * 2011-07-09 2013-01-17 The Trustees Of Columbia University In The City Of New York Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENG ET AL.: "Biomolecular Events in Cancer Revealed by Attractor Metagenes", PLOS, vol. 9, no. ISS. 2, 21 February 2013 (2013-02-21), pages 1 - 14 *
CHENG ET AL.: "Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. ISS. 1, 17 April 2013 (2013-04-17), pages 1 - 12 *

Also Published As

Publication number Publication date
WO2013163134A2 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX2013010343A (en) Compositions and methods for transplantation of colon microbiota.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
EP2971128A4 (en) Biomarkers for diagnosis of lung diseases and methods of use thereof
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
UA115034C2 (en) Immunoconjugate for use in the treatment of cancer or inflammatory disorder
MX2013002084A (en) Biomarkers and methods of treatment.
UA115122C2 (en) Cd3-binding molecules capable of binding to human and non-human cd3
EP2598873A4 (en) Biomarkers for prostate cancer and methods using the same
WO2012173846A3 (en) Peptidomimetic macrocycles
MY192513A (en) Compositions and methods related to diagnosis of prostate cancer
MX358474B (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases.
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
EP2723866A4 (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2013093115A3 (en) Marker sequences for breast cancer and the use thereof
WO2013087929A3 (en) Method for identifying marker sequences for gynaecological malignant tumours
PH12014502582B1 (en) Anti-TG2 Antibodies and Methods for Using the Same
WO2013163134A3 (en) Biomolecular events in cancer revealed by attractor metagenes
TR201907907T4 (en) Methods of increasing the forced expiratory volume in asthmatic patients using benralizumab.
MX368474B (en) Methods for improving asthma symptoms using benralizumab.
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
FR2979346B1 (en) NANOCORPS ANTI-VCAM-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13781590

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13781590

Country of ref document: EP

Kind code of ref document: A2